Peptide Comparisons

BPC-157 vs TB-500

BPC-157 and TB-500 are both research-stage peptides with proposed tissue-repair properties, and they are among the most commonly co-administered compounds in the biohacking and recovery community. Despite their similar reputation, they differ meaningfully in origin, mechanism, and the body of preclinical evidence supporting them. Neither has established human clinical trial data for any therapeutic indication.

View comparison →

CJC-1295 vs Hexarelin vs Ipamorelin

CJC-1295, hexarelin, and ipamorelin are three growth hormone secretagogues that increase GH and IGF-1, but via different receptors and with different side-effect profiles. CJC-1295 acts on the GHRH receptor; hexarelin and ipamorelin act on the ghrelin receptor (GHS-R1a). None are FDA-approved; all are prohibited by WADA in and out of competition. Understanding their differences is essential for any comparative research context.

View comparison →

Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are both injectable incretin-based therapies with FDA approval for type 2 diabetes and obesity — but their receptor targets differ in a clinically meaningful way. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Head-to-head trial data (SURMOUNT-5) now show tirzepatide produces meaningfully greater weight loss, though both are highly effective and have large RCT evidence bases.

View comparison →

Sermorelin vs Tesamorelin

Sermorelin and tesamorelin are both synthetic GHRH analogs that stimulate the pituitary to release growth hormone — but they differ in regulatory standing, evidence depth, and cost profile. Tesamorelin (Egrifta) retains an active FDA approval for a specific indication; sermorelin's original FDA approval for pediatric GH deficiency was withdrawn from the commercial market but it remains widely available as a compounded drug. Both are WADA-prohibited in competitive sport.

View comparison →